Annaliesa Anderson | Chief Scientific Officer, Bacterial Vaccines And The Hospital Business Unit, Pfizer
Pfizer | United States

Annaliesa Anderson, Chief Scientific Officer, Bacterial Vaccines And The Hospital Business Unit, Pfizer, Pfizer

Annaliesa Anderson PhD FAAM, has over 20 years of pharmaceutical research experience and is currently the Chief Scientific Officer for Bacterial Vaccines at Pfizer Inc. Her responsibilities include infectious disease vaccine R and D, surveillance and the assessment of the immunopathology of bacterial colonization and disease. Dr Andersons experience includes leadership roles for bacterial vaccine programs directed at the prevention of diseases due to Neisseria meningitidisStaphylococcus aureus and Clostridium difficile and Enterococcus sp. In this role, she has made substantial contributions to vaccine antigen discovery, preclinical proof of concept, clinical proof of concept and recently the licensure of the N. meningitidis serogroup B vaccine Trumenba®.

Appearances:



Oct 30th Day 2 @ 12:05

Pfizer’s Ph3 C.diff

last published: 16/Sep/19 14:05 GMT

back to speakers

Sign Up for Event Updates